Tue, May 1, 2012
Mon, April 30, 2012

Christopher Raymond Maintained (BIIB) at Buy with Increased Target to $159 on, May 1st, 2012

Christopher Raymond of Piper Sandler, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $140 to $159 on, May 1st, 2012.

Christopher has made no other calls on BIIB in the last 4 months.



There is 1 other peer that has a rating on BIIB. Out of the 1 peers that are also analyzing BIIB, 0 agree with Christopher's Rating of Hold.



This is the rating of the analyst that currently disagrees with Christopher


  • Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $140 on, Friday, February 10th, 2012